Advertisement

Drugs

, Volume 79, Issue 18, pp 1965–1976 | Cite as

Dimethyl Fumarate: A Review in Relapsing-Remitting MS

  • Hannah A. BlairEmail author
Adis Drug Evaluation

Abstract

Dimethyl fumarate (Tecfidera®) is approved for the treatment of relapsing forms of multiple sclerosis (MS). Based on evidence from the clinical trial and real-world settings, dimethyl fumarate is an effective treatment in this patient population, with benefits maintained over the longer term. In the pivotal, placebo-controlled phase III DEFINE and CONFIRM trials in adults with relapsing-remitting multiple sclerosis (RRMS), twice-daily dimethyl fumarate reduced clinical relapse and MRI measures of disease activity and improved some aspects of health-related quality of life (HR-QoL). Reduced disability progression was also observed with dimethyl fumarate in DEFINE. Results in predominantly East Asian patients (APEX trial) were reflective of those seen in DEFINE and CONFIRM. Dimethyl fumarate had an acceptable tolerability profile. The most common adverse events were flushing and gastrointestinal events, which were of mild or moderate severity and appear to be largely manageable. Thus twice-daily dimethyl fumarate remains an effective treatment option for use in patients with RRMS, with the convenience of oral administration.

Notes

Acknowledgements

During the review process, the manufacturer of dimethyl fumarate (Biogen) was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Hannah Blair is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43.PubMedCrossRefGoogle Scholar
  2. 2.
    Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96–120.PubMedCrossRefGoogle Scholar
  3. 3.
    National Multiple Sclerosis Society. MS. 2019. http://www.nationalmssociety.org. Accessed 13 Nov 2019.
  4. 4.
    Linker RA, Chan A. Navigating choice in multiple sclerosis management. Neurol Res Pract. 2019.  https://doi.org/10.1186/s42466-019-0005-5.CrossRefGoogle Scholar
  5. 5.
    Costello K, Kalb R. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. 2014. http://www.nationalmssociety.org. Accessed 13 Nov 2019.
  6. 6.
    Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur J Neurol. 2019;26(1):27–40.PubMedCrossRefGoogle Scholar
  7. 7.
    Kim W, Zandona ME, Kim SH, et al. Oral disease-modifying therapies for multiple sclerosis. J Clin Neurol. 2015;11(1):9–19.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Biogen Inc. Tecfidera® (dimethyl fumarate) delayed-release capsules, for oral use: US prescribing information. 2017. http://www.dailymed.nlm.nih.gov. Accessed 13 Nov 2019.
  9. 9.
    European Medicines Agency. Tecfidera® (dimethyl fumarate) gastro-resistant hard capsules: summary of product characteristics. 2014. http://www.ema.europa.eu. Accessed 13 Nov 2019.
  10. 10.
    Burness CB, Deeks ED. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS Drugs. 2014;28(4):373–87.PubMedCrossRefGoogle Scholar
  11. 11.
    Deeks ED. Dimethyl fumarate: a review in relapsing-remitting MS. Drugs. 2016;76(2):243–54.PubMedCrossRefGoogle Scholar
  12. 12.
    Yadav SK, Soin D, Ito K, et al. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis. J Mol Med. 2019;97(4):463–72.PubMedCrossRefGoogle Scholar
  13. 13.
    Diebold M, Sievers C, Bantug G, et al. Dimethyl fumarate influences innate and adaptive immunity in Multiple Sclerosis. J Autoimmun. 2018;86:39–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Kornberg MD, Bhargava P, Kim PM, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018;360(6387):449–53.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Carlstrom KE, Ewing E, Granqvist M, et al. Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes. Nat Commun. 2019;10(1):3081.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Breuer J, Herich S, Schneider-Hohendorf T, et al. Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium. Mult Scler. 2017;24(14):1871–82.CrossRefGoogle Scholar
  17. 17.
    Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–107.PubMedCrossRefGoogle Scholar
  18. 18.
    Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–97.PubMedCrossRefGoogle Scholar
  19. 19.
    Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017;23(2):253–65.PubMedCrossRefGoogle Scholar
  20. 20.
    Viglietta V, Miller D, Bar-Or A, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2(2):103–18.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Kappos L, Giovannoni G, Gold R, et al. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Eur J Neurol. 2015;22(4):664–71.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Fernandez O, Giovannoni G, Fox RJ, et al. Efficacy and safety of delayed-release dimethyl fumarate for relapsing-remitting multiple sclerosis in prior interferon users: an integrated analysis of DEFINE and CONFIRM. Clin Ther. 2017;39(8):1671–9.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Fox RJ, Gold R, Phillips JT, et al. Efficacy and tolerability of delayed-release dimethyl fumarate in Black, Hispanic, and Asian patients with relapsing-remitting multiple sclerosis: post hoc integrated analysis of DEFINE and CONFIRM. Neurol Ther. 2017;6(2):175–87.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Gold R, Giovannoni G, Phillips JT, et al. Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). Mult Scler. 2015;21(1):57–66.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Bar-Or A, Gold R, Kappos L, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol. 2013;260(9):2297–305.PubMedCrossRefGoogle Scholar
  26. 26.
    Hutchinson M, Fox RJ, Miller DH, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol. 2013;260(9):2286–96.PubMedCrossRefGoogle Scholar
  27. 27.
    Gold R, Giovannoni G, Phillips JT, et al. Overall safety and efficacy through 10 years of treatment with delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis [abstract no. P1397 + poster]. Mult Scler. 2019;25(S2):772–3.Google Scholar
  28. 28.
    Giovannoni G, Gold R, Kappos L, et al. Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: integrated analysis of DEFINE and CONFIRM. Mult Scler J Exp Transl Clin. 2016.  https://doi.org/10.1177/2055217316634111.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Arnold DL, Gold R, Kappos L, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 DEFINE study. J Neurol. 2014;261(9):1794–802.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Miller DHF, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015;84(11):1145–52.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Nakamura K, Mokliatchouk O, Arnold DL, et al. Effects of dimethyl fumarate on brain volume change in relapsing-remitting multiple sclerosis: a pooled analysis of the phase 3 DEFINE and CONFIRM studies [abstract no. P3.2-064]. Neurology. 2019;92(Suppl 15).Google Scholar
  32. 32.
    Arnold DL, Gold R, Kappos L, et al. Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol. 2014;261(12):2429–37.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Arnold DL, Fox RJ, Gold R, et al. MRI outcomes at seven years in relapsing-remitting multiple sclerosis patients treated with delayed-release dimethyl fumarate in DEFINE, CONFIRM, and ENDORSE [abstract no. S12.002]. Neurology. 2017;88:Suppl 16.Google Scholar
  34. 34.
    Havrdova E, Giovannoni G, Gold R, et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol. 2017;24(5):726–33.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Kappos L, Gold R, Arnold DL, et al. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study. Mult Scler. 2014;20(2):243–52.PubMedCrossRefGoogle Scholar
  36. 36.
    Kita M, Fox RJ, Phillips JT, et al. Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler. 2014;20(2):253–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Kita M, Fox RJ, Gold R, et al. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. Clin Ther. 2014;36(12):1958–71.PubMedCrossRefGoogle Scholar
  38. 38.
    Saida T, Yamamura T, Kondo T, et al. A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries. BMC Neurol. 2019;19(1):5.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Kondo T, Kawachi I, Onizuka Y, et al. Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension. Mult Scler J Exp Transl Clin. 2019.  https://doi.org/10.1177/2055217319864974.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Mori M, Ohashi T, Onizuka Y, et al. Efficacy and safety of dimethyl fumarate in treatment-naive Japanese patients with multiple sclerosis: interim analysis of the randomized placebo-controlled study. Mult Scler J Exp Transl Clin. 2019.  https://doi.org/10.1177/2055217319852727.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Lorscheider J, Benkert P, Lienert C, et al. Fingolimod vs. dimethyl fumarate in relapsing-remitting multiple sclerosis: propensity score matched comparison in a large observational data set [abstract no. P1145]. Mult Scler. 2017;23 (Suppl 3):601–2.Google Scholar
  42. 42.
    Mallucci G, Annovazzi P, Miante S, et al. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. J Neurol. 2018;265(8):1850–9.PubMedCrossRefGoogle Scholar
  43. 43.
    D’Amico E, Zanghi A, Callari G, et al. Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in relapsing-remitting multiple sclerosis: an Italian real-word multicenter experience. Ther Adv Neurol Disord. 2018.  https://doi.org/10.1177/1756286418796404.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Pandey K, Giles K, Balashov K, et al. Safety and effectiveness of delayed-release dimethyl fumarate maintained over 4-years in multiple sclerosis patients treated in routine medical practice [abstract no. P649 + poster]. Mult Scler. 2019;25(S2):318–9.Google Scholar
  45. 45.
    Laplaud D-A, Casey R, Barbin L, et al. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. 2019;93:e635–46.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Kalincik T, Kubala Havrdova E, Horakova D, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(4):458–68.PubMedCrossRefGoogle Scholar
  47. 47.
    Giles K, Balashov K, Jones CC, et al. Real-world efficacy of delayed-release dimethyl fumarate in early multiple sclerosis: interim results from ESTEEM [abstract no. P595]. Mult Scler. 2018;24(S2):289–90.Google Scholar
  48. 48.
    Ontaneda D, Nicholas J, Carraro M, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Mult Scler Relat Disord. 2019;27:101–11.PubMedCrossRefGoogle Scholar
  49. 49.
    Nicholas J, Carraro M, Ontaneda D, et al. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide on the risk of relapse in MS patients switching from first-generation platform therapies in the US [abstract no. 374]. Neurology. 2018;90(Suppl 15).Google Scholar
  50. 50.
    Cohan SL, Moses H, Calkwood J, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord. 2018;22:27–34.PubMedCrossRefGoogle Scholar
  51. 51.
    Braune S, Grimm S, van Hovell P, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol. 2018;265(12):2980–92.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Vollmer B, Ontaneda D, Bandyopadhyay A, et al. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract. 2018;8(4):292–301.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Mirabella M, Prosperini L, Lucchini M, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: an Italian, multicenter, real-world study. CNS Drugs. 2018;32(10):963–70.PubMedCrossRefGoogle Scholar
  54. 54.
    Miclea A, Leussink VI, Hartung HP, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study. J Neurol. 2016;263(8):1626–32.PubMedCrossRefGoogle Scholar
  55. 55.
    Granqvist M, Burman J, Gunnarsson M, et al. Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS. Mult Scler. 2019.  https://doi.org/10.1177/1352458519866600.CrossRefPubMedGoogle Scholar
  56. 56.
    Sloane J, Phillips JT, Calkwood J, et al. Delayed-release dimethyl fumarate demonstrated no difference in clinical outcomes versus fingolimod in patients with relapsing-remitting multiple sclerosis: results from the real-world EFFECT study [abstract no. P1.362]. Neurology. 2018;90(Suppl):15.Google Scholar
  57. 57.
    Vollmer BL, Nair KV, Sillau S, et al. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2019;6(2):252–62.PubMedGoogle Scholar
  58. 58.
    Min J, Sloane J, Phillips JT, et al. Leveraging real-world evidence for comparative effectiveness: delayed-release dimethyl fumarate vs. fingolimod and glatiramer acetate in RRMS [abstract no. P016]. Mult Scler. 2018;24(Suppl 1):17–8.Google Scholar
  59. 59.
    Lee A, Pike J, Edwards MR, et al. Quantifying the benefits of dimethyl fumarate over beta Interferon and glatiramer acetate therapies on work productivity outcomes in MS patients. Neurol Ther. 2017;6(1):79–90.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Rock M, Pike J, Jones E, et al. Physician reported adherence in MS patients treated with injectable platform therapies versus delayed-release dimethyl fumarate: findings from a real-world cross-sectional study [abstract no. PND117]. Value Health. 2018;21(Suppl 3):S348.Google Scholar
  61. 61.
    Rock M, Pike J, Jones E, et al. Reduced healthcare resource utilisation for patients treated with delayed release dimethyl fumarate vs injectable therapies: findings from a real-world cross-sectional study of MS patients [abstract no. PND79]. Value Health. 2018;21(Suppl 3):S342.Google Scholar
  62. 62.
    Brochet B, Tourbah A, Castelnovo G, et al. Effectiveness of dimethyl fumarate on disease activity and patient-reported outcomes in French subjects with relapsing-remitting multiple sclerosis in the real-world: a subgroup analysis of PROTEC [abstract no. P1135]. Mult Scler. 2017;23(Suppl 3):594–5.Google Scholar
  63. 63.
    Buron MD, Chalmer TA, Sellebjerg F, et al. Comparative effectiveness of teriflunomide and dimethyl fumarate: a nationwide cohort study. Neurology. 2019;92(16):e1811–20.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Forsberg L, Kagstrom S, Leandersson A, et al. A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5) [abstract no. EP1682]. Mult Scler. 2017;23(Suppl 3):884–5.Google Scholar
  65. 65.
    Moiola L, Esposito F, Di Cristinzi M, et al. Comparative effectiveness of dimethylfumarate and fingolimod in an Italian monocentric cohort of relapsing remitting multiple sclerosis [abstract no. 228]. Eur J Neurol. 2019;26(Suppl 1):677.Google Scholar
  66. 66.
    Kresa-Reahl K, Repovic P, Robertson D, et al. Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a prospective observational study. Clin Ther. 2018;40(12):2077–87.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Ochi H, Niino M, Onizuka Y, et al. 72-week safety and tolerability of dimethyl fumarate in Japanese patients with relapsing-remitting multiple sclerosis: analysis of the randomised, double blind, placebo-controlled, phase III APEX study and its open-label extension. Adv Ther. 2018;35(10):1598–611.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Phillips JT, Selmaj K, Gold R, et al. Clinical significance of gastrointestinal and flushing events in patients with delayed-release dimethyl fumarate. Int J MS Care. 2015;17(5):236–43.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Phillips JT, Hutchinson M, Fox R, et al. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel. Mult Scler Relat Disord. 2014;3(4):513–9.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Fox EJ, Vasquez A, Grainger W, et al. Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE). Int J MS Care. 2016;18(1):9–18.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Phillips JT, Erwin AA, Agrella S, et al. Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a DELPHI study. Neurol Ther. 2015;4(2):137–46.CrossRefGoogle Scholar
  72. 72.
    Koulinska I, Riester K, Chalkias S, et al. Effect of bismuth subsalicylate on gastrointestinal tolerability in healthy volunteers receiving oral delayed-release dimethyl fumarate: PREVENT, a randomized, multicenter, double-blind, placebo-controlled study. Clin Ther. 2018;40(12):2021-30.e1.CrossRefGoogle Scholar
  73. 73.
    O’Gorman J, Russell HK, Li J, et al. Effect of aspirin pretreatment or slow dose titration on flushing and gastrointestinal events in healthy volunteers receiving delayed-release dimethyl fumarate. Clin Ther. 2015;37(7):1402–19.PubMedCrossRefGoogle Scholar
  74. 74.
    Rog D, Cader S, Harrower T, et al. Effect of aspirin on flushing in relapsing-remitting multiple sclerosis patients receiving delayed-release dimethyl fumarate [abstract no. P1246]. Mult Scler. 2016;22(Suppl 3):656–7.Google Scholar
  75. 75.
    Mehta D, Miller C, Arnold DL, et al. Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice. Neurology. 2019;92(15):e1724–38.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Diebold M, Altersberger V, Decard BF, et al. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Mult Scler. 2019;25(12):1682–5.PubMedCrossRefGoogle Scholar
  77. 77.
    Garcia J, Chavez Baroni H, Dubessy AL, et al. Progressive multifocal leukoencephalopathy in a patient treated by dimethyl fumarate for multiple sclerosis with no lymphopenia but exhausted T lymphocyte subpopulations [abstract no. P1042]. Mult Scler J. 2019;25(Suppl 2):556.Google Scholar
  78. 78.
    Baharnoori M, Gonzalez CT, Chua A, et al. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. Mult Scler Relat Disord. 2018;20:51–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Gold R, Schlegel E, Elias-Hamp B, et al. Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE). Ther Adv Neurol Disord. 2018.  https://doi.org/10.1177/1756286418768775.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Min J, Cohan S, Alvarez E, et al. Real-world characterization of dimethyl fumarate-related gastrointestinal events in multiple sclerosis: management strategies to improve persistence on treatment and patient outcomes. Neurol Ther. 2019;8:109–19.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Sejbaek T, Nybo M, Petersen T, et al. Real-life persistence and tolerability with dimethyl fumarate. Mult Scler Relat Disord. 2018;24:42–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Prosperini L, Lanzillo R, Fantozzi R, et al. A multi-centre observational analysis of persistence to treatment in the new MS era: the RESPECT study [abstract no. EP1792]. Mult Scler. 2017;23(Suppl 3):945–6.Google Scholar
  83. 83.
    Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017;264(12):2351–74.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Eagle T, Stuart F, Chua AS, et al. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2017;18:196–201.PubMedCrossRefGoogle Scholar
  85. 85.
    Mayer L, Fink MK, Sammarco C, et al. Management strategies to facilitate optimal outcomes for patients treated with delayed-release dimethyl fumarate. Drug Saf. 2018;41(4):347–56.PubMedCrossRefGoogle Scholar
  86. 86.
    Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273–9.PubMedCrossRefGoogle Scholar
  87. 87.
    National Institute for Health and Care Excellence. Dimethyl fumarate for treating relapsing-remitting multiple sclerosis. 2014. http://www.nice.org.uk/guidance/ta320. Accessed 13 Nov 2019.
  88. 88.
    Chan A, Cutter G, Fox RJ, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. J Comp Eff Res. 2017;6(4):313–23.PubMedCrossRefGoogle Scholar
  89. 89.
    Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin. 2014;30(4):613–27.PubMedCrossRefGoogle Scholar
  90. 90.
    Cutter G, Sormani MP, Betts M, et al. Comparative effectiveness of delayed-release dimethyl fumarate vs. other disease-modifying therapies in patients with multiple sclerosis: a network meta-analysis of real-world evidence [abstract no. P1394 + poster]. Mult Scler. 2019;25(S2):770.Google Scholar
  91. 91.
    Zagmutt FJ, Carroll CA. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis. Int J Neurosci. 2015;125(11):798–807.PubMedCrossRefGoogle Scholar
  92. 92.
    Freedman MS, Montalban X, Miller AE, et al. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: assessing absolute differences using a number needed to treat analysis. Mult Scler Relat Disord. 2016;10:204–12.PubMedCrossRefGoogle Scholar
  93. 93.
    Nixon R, Bergvall N, Tomic D, et al. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther. 2014;31(11):1134–54.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Fox RJ, Chan A, Zhang A, et al. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Curr Med Res Opin. 2017;33(2):175–83.PubMedCrossRefGoogle Scholar
  95. 95.
    Biogen Inc. Vumerity™ (diroximel fumarate) delayed-release capsules, for oral use. 2019. http://www.vumerity.com. Accessed 13 Nov 2019.
  96. 96.
    Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–88.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations